Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Diabetes

FreeStyle Libre 2 Cleared for Use in Adults and Pediatric Patients With Diabetes

Diana Ernst, RPh

June 18, 2020

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes.

Cardiovascular and Metabolic Disorders

Combination Therapy of Bempedoic Acid, Ezetimibe Now Available as Adjunct to Statins

Diana Ernst, RPh

June 10, 2020

Nexlizet (bempedoic acid and ezetimibe; Esperion) is now available for use as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Androgen and Reproductive Disorders

FDA Approves Treatment for Heavy Menstrual Bleeding Due to Uterine Fibroids

Diana Ernst, RPh

June 3, 2020

The FDA has approved Oriahnn™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules; AbbVie) for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.

Type 2 Diabetes

FDA: Unacceptable NDMA Levels Identified in Certain Metformin ER Products

Diana Ernst, RPh

June 2, 2020

Specifically, unacceptable levels of this potentially carcinogenic impurity have been identified in products manufactured by 5 different firms.

Diabetes

Dasiglucagon Under Review for Severe Hypoglycemia

Diana Ernst, RPh

June 1, 2020

The FDA has accepted for review the New Drug Application for dasiglucagon HypoPal® Rescue Pen (Zealand Pharma) for the treatment of severe hypoglycemia.

General Endocrinology

FDA Updates Essure Adverse Events Page to Include 2019 Reports

Diana Ernst, RPh

May 8, 2020

The FDA has updated its “Problems Reported with Essure” webpage to include medical device reports received in 2019.

Pediatric Endocrinology

Leuprolide Acetate Approved for Central Precocious Puberty

Diana Ernst, RPh

May 6, 2020

The FDA has approved Fensolvi (leuprolide acetate; Tolmar Pharmaceuticals) for the treatment of pediatric patients 2 years of age and older with central precocious puberty.

Obesity

Update on Potential Risks Associated With Liquid-Filled Intragastric Balloons

Diana Ernst, RPh

May 5, 2020

Post-approval study results on the risk of hyperinflation, acute pancreatitis, and death associated with the use of liquid-filled intragastric balloons have been made available by the FDA.

General Endocrinology

FDA Urges Individuals Who Have Recovered From COVID-19 to Donate Plasma

Diana Ernst, RPh

April 22, 2020

The FDA has launched a new webpage with information for recovered individuals who were infected with coronavirus disease 2019 (COVID-19) on where they can go to donate plasma to aid in the treatment of severely ill patients.

General Endocrinology

Long-Acting Therapy for Growth Hormone Deficiency Receives Orphan Designation

Diana Ernst, RPh

April 20, 2020

The FDA has granted Orphan Drug designation to TransCon hGH (lonapegsomatropin; Ascendis Pharma), a long-acting prodrug of somatropin, for the treatment for growth hormone deficiency.

Next post in General Endocrinology